Identification of Risk Factors for Low Lymphocyte Count in Patients with Type 2 Diabetes: An Analysis of Data From the SAVOR Study
Diabetes Mellitus, Type 2
40 Years +
Endpoint Classification: -
Intervention Model: -
Primary Purpose: -
Verified 01 Nov 2016 by AstraZeneca
Bristol Myers Squibb
No locations available
|Patients treated with saxagliptin or placebo|
Patients will be treated with saxagliptin or placebo, on top of whatever baseline treatment for diabetes the patient is already receiving.
|Patients currently or previously on treatment|
Patients currently or previously on (within 6 months) treatment with DPP4 inhibitors and/or GLP-1 mimetics are excluded.